A small-molecule inhibitor of BCL10-MALT1 interaction abrogates progression of diffuse large B cell lymphoma
Journal of Clinical Investigation · 2025
DOI: 10.1172/jci164573 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Investigation, 2025. Verfasst von Heejae Kang und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and. Hauptthemen laut MEDLINE: Mucosa-Associated Lymphoid Tissue Lymphoma Translocation 1 Protein, Lymphoma, Large B-Cell, Diffuse, B-Cell CLL-Lymphoma 10 Protein, Neoplasm Proteins. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, NHLBI NIH HHS, NIH.
Abstract (Originalsprache)
Diffuse large B cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma, and the activated B cell–like subtype (ABC-DLBCL) is associated with particularly poor outcome. Many ABC-DLBCLs harbor gain-of-function mutations that cause inappropriate assembly of the CARMA1-BCL10-MALT1 (CBM) signalosome, a cytoplasmic complex that drives downstream NF-κB signaling. MALT1 is the effector protein of the CBM signalosome such that its recruitment to the signalosome via interaction with BCL10 allows it to exert both protease and scaffolding activities that together synergize in driving NF-κB. Here, we demonstrate that a molecular groove located between two adjacent immunoglobulin-like domains within MALT1 represents a binding pocket for BCL10. Leveraging this discovery, we performed an in silico screen to identify small molecules that dock within this MALT1 groove and act as BCL10-MALT1 protein-protein interaction (PPI) inhibitors. We report the identification of M1i-124 as a first-in-class compound that blocks BCL10-MALT1 interaction, abrogates MALT1 scaffolding and protease activities, promotes degradation of BCL10 and MALT1 proteins, and specifically targets ABC-DLBCLs characterized by dysregulated MALT1. Our findings demonstrate that small-molecule inhibitors of BCL10-MALT1 interaction can function as potent agents to block MALT1 signaling in selected lymphomas, and provide a road map for clinical development of a new class of precision-medicine therapeutics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology and.
- Department of Pediatrics, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
- Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.
- Department of Pathology, University of Michigan Medical School, Ann Arbor, Michigan, USA.
- Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
- UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.
Förderung
- NIAID NIH HHS
- NHLBI NIH HHS
- NIH
- St. Baldrick’s Foundation
- UPMC Institute for Precision Medicine
- CHP Foundation
- Mario Lemieux Foundation
Zitieren
APA
Kang, H., Maurer, L. M., Cheng, J., Smyers, M., Klei, L. R., Hu, D., Hofstatter Azambuja, J., Murai, M. J., Mady, A., Ahmad, E., Trotta, M., Klei, H. B., Liu, M., Ekambaram, P., Nikolovska-Coleska, Z., Chen, B. B., McAllister-Lucas, L. M., & Lucas, P. C. (2025). A small-molecule inhibitor of BCL10-MALT1 interaction abrogates progression of diffuse large B cell lymphoma. Journal of Clinical Investigation. https://doi.org/10.1172/jci164573
Vancouver
Kang H, Maurer LM, Cheng J, Smyers M, Klei LR, Hu D, et al. A small-molecule inhibitor of BCL10-MALT1 interaction abrogates progression of diffuse large B cell lymphoma. Journal of Clinical Investigation. 2025. doi:10.1172/jci164573
BibTeX
@article{Kang2025,
author = {Kang, Heejae and Maurer, Lisa M and Cheng, Jing and Smyers, Mei and Klei, Linda R and Hu, Dong and Hofstatter Azambuja, Juliana and Murai, Marcelo J and Mady, Ahmed and Ahmad, Ejaz and Trotta, Matthew and Klei, Hanna B and Liu, Minda and Ekambaram, Prasanna and Nikolovska-Coleska, Zaneta and Chen, Bill B and McAllister-Lucas, Linda M and Lucas, Peter C},
title = {A small-molecule inhibitor of BCL10-MALT1 interaction abrogates progression of diffuse large B cell lymphoma},
journal = {Journal of Clinical Investigation},
year = {2025},
doi = {10.1172/jci164573}
}
EUVIMED